Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients: 24-week immunological outcome

Nicola Gianotti; Alessandro Soria; Laura Galli; Barbara Giudici; Giuliana Fusetti; Adriano Lazzarin; Enzo Boeri; Antonella Castagna

doi:10.1097/00002030-200403260-00018

Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients: 24-week immunological outcome

Nicola Gianotti, Alessandro Soria, Laura Galli, Barbara Giudici, Giuliana Fusetti, Adriano Lazzarin, Enzo Boeri, Antonella Castagna

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

The best salvage therapy for protease inhibitor (PI)-resistant HIV-infected patients is still controversial. We measured changes in viral load and CD4 T-lymphocyte counts in 40 PI-resistant patients receiving boosted PI-including or PI-sparing antiretroviral therapy. At multivariate analysis, the only independent predictor of CD4 T-lymphocyte changes at week 24 was a boosted PI-including regimen. In PI-resistant HIV-infected patients, a boosted PI regimen preserves CD4 T lymphocytes from depletion in the medium term compared with a PI-sparing regimen.

Original language	English
Pages (from-to)	821-823
Number of pages	3
Journal	AIDS (London, England)
Volume	18
Issue number	5
DOIs	https://doi.org/10.1097/00002030-200403260-00018
Publication status	Published - Mar 26 2004

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1097/00002030-200403260-00018

Fingerprint Dive into the research topics of 'Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients: 24-week immunological outcome'. Together they form a unique fingerprint.

Cite this

Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients : 24-week immunological outcome. / Gianotti, Nicola; Soria, Alessandro; Galli, Laura; Giudici, Barbara; Fusetti, Giuliana; Lazzarin, Adriano; Boeri, Enzo; Castagna, Antonella.

In: AIDS (London, England), Vol. 18, No. 5, 26.03.2004, p. 821-823.

Research output: Contribution to journal › Article › peer-review

Gianotti, Nicola ; Soria, Alessandro ; Galli, Laura ; Giudici, Barbara ; Fusetti, Giuliana ; Lazzarin, Adriano ; Boeri, Enzo ; Castagna, Antonella. / Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients : 24-week immunological outcome. In: AIDS (London, England). 2004 ; Vol. 18, No. 5. pp. 821-823.

@article{8f9e43ebaf754be78fd390a5dcb01505,

title = "Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients: 24-week immunological outcome",

abstract = "The best salvage therapy for protease inhibitor (PI)-resistant HIV-infected patients is still controversial. We measured changes in viral load and CD4 T-lymphocyte counts in 40 PI-resistant patients receiving boosted PI-including or PI-sparing antiretroviral therapy. At multivariate analysis, the only independent predictor of CD4 T-lymphocyte changes at week 24 was a boosted PI-including regimen. In PI-resistant HIV-infected patients, a boosted PI regimen preserves CD4 T lymphocytes from depletion in the medium term compared with a PI-sparing regimen.",

author = "Nicola Gianotti and Alessandro Soria and Laura Galli and Barbara Giudici and Giuliana Fusetti and Adriano Lazzarin and Enzo Boeri and Antonella Castagna",

year = "2004",

month = mar,

day = "26",

doi = "10.1097/00002030-200403260-00018",

language = "English",

volume = "18",

pages = "821--823",

journal = "AIDS",

issn = "0269-9370",

publisher = "NLM (Medline)",

number = "5",

}

TY - JOUR

T1 - Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients

T2 - 24-week immunological outcome

AU - Gianotti, Nicola

AU - Soria, Alessandro

AU - Galli, Laura

AU - Giudici, Barbara

AU - Fusetti, Giuliana

AU - Lazzarin, Adriano

AU - Boeri, Enzo

AU - Castagna, Antonella

PY - 2004/3/26

Y1 - 2004/3/26

N2 - The best salvage therapy for protease inhibitor (PI)-resistant HIV-infected patients is still controversial. We measured changes in viral load and CD4 T-lymphocyte counts in 40 PI-resistant patients receiving boosted PI-including or PI-sparing antiretroviral therapy. At multivariate analysis, the only independent predictor of CD4 T-lymphocyte changes at week 24 was a boosted PI-including regimen. In PI-resistant HIV-infected patients, a boosted PI regimen preserves CD4 T lymphocytes from depletion in the medium term compared with a PI-sparing regimen.

AB - The best salvage therapy for protease inhibitor (PI)-resistant HIV-infected patients is still controversial. We measured changes in viral load and CD4 T-lymphocyte counts in 40 PI-resistant patients receiving boosted PI-including or PI-sparing antiretroviral therapy. At multivariate analysis, the only independent predictor of CD4 T-lymphocyte changes at week 24 was a boosted PI-including regimen. In PI-resistant HIV-infected patients, a boosted PI regimen preserves CD4 T lymphocytes from depletion in the medium term compared with a PI-sparing regimen.

UR - http://www.scopus.com/inward/record.url?scp=2042469458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2042469458&partnerID=8YFLogxK

U2 - 10.1097/00002030-200403260-00018

DO - 10.1097/00002030-200403260-00018

M3 - Article

C2 - 15075522

AN - SCOPUS:2042469458

VL - 18

SP - 821

EP - 823

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 5

ER -

Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients: 24-week immunological outcome

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this